RT Journal Article
SR Electronic
T1 Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 639
OP 647
DO 10.21873/anticanres.16853
VO 44
IS 2
A1 SAKAMOTO, SHINICHI
A1 ANDO, KEISUKE
A1 PAE, SANGJON
A1 ZHAO, XUE
A1 SAKAI, KAZUKO
A1 SATO, KODAI
A1 SAITO, SHINPEI
A1 YAMADA, YASUTAKA
A1 RII, JUNRYO
A1 GOTO, YUSUKE
A1 SAZUKA, TOMOKAZU
A1 IMAMURA, YUSUKE
A1 ANZAI, NAOHIKO
A1 AKAKURA, KOICHIRO
A1 NISHIO, KAZUTO
A1 ICHIKAWA, TOMOHIKO
YR 2024
UL http://ar.iiarjournals.org/content/44/2/639.abstract
AB Background/Aim: The prognostic significance of androgen receptor amplification (AR amp) in cell-free DNA (cfDNA) was studied in Japanese patients with castration-resistant prostate cancer (CRPC). Patients and Methods: A total of 120 serum samples were obtained from 38 patients with CRPC. Serum cfDNA was purified and the AR copy number was determined. Factors associated with progression-free survival (PFS) and overall survival (OS) were statistically investigated. Results: The number of patients administered enzalutamide (Enza)/abiraterone (Abi)/docetaxel (DTX) was 33/25/11, respectively. The median PSA was 16.5 ng/ml. Thirty patients (79%) had bone metastases and three patients (7.9%) had lung metastases. The median follow-up was 655 days. The median initial AR copy number was 1.27 (1.10-11.50); an AR copy number of 1.27 or higher was defined as an AR-amp. Regarding PFS, the presence of AR-amp, Gleason score (GS), and ALP were significant factors in univariate analysis. In multivariate analysis, AR amplification was an independent prognostic factor (hazard ratio=7.7, p=0.0035). For OS, PSA and AR-amp were significant factors. In multivariate analysis, AR-amp (hazard ratio=4.65, p=0.0188) was the only independent prognostic factor. Conclusion: AR-amp was associated with high nadir PSA and low iPSA/PSA ratio. AR-amp was significantly associated with poor prognosis in Japanese patients with CRPC.